The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC.
 
Anna C. Ferrari
Research Funding - Novartis
 
Joshi J. Alumkal
No Relationships to Disclose
 
Mark N. Stein
No Relationships to Disclose
 
Tina M. Mayer
No Relationships to Disclose
 
Sarah Torneten
No Relationships to Disclose
 
James Babb
No Relationships to Disclose
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Robert S. DiPaola
No Relationships to Disclose
 
Tomasz M. Beer
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Novartis; Sotio
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Research & Development (Inst); Medivation (Inst); OncoGenex (Inst); Sotio (Inst)